Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

2.810 -1.750 (-38.38%)
Streaming Delayed Price Updated: 2:36 PM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,923,244
Open 3.600
Bid (Size) 2.810 (600)
Ask (Size) 2.820 (1,400)
Prev. Close 4.560
Today's Range 2.200 - 3.720
52wk Range 3.420 - 7.950
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's session ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill

Performance

YTD
-53.9%
-53.9%
1 Month
-35.4%
-35.4%
3 Month
-38.2%
-38.2%
6 Month
-35.3%
-35.3%
1 Year
-45.0%
-45.0%

More News

Read More
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
TriSalus Life Sciences Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
TriSalus Life Sciences (NASDAQ:TLSI) Swings to Surprise Net Profit in Q1, But Revenue Miss Tempers Outlook ↗
Via Chartmill
TriSalus Life Sciences Inc (NASDAQ:TLSI) Reports Q4 Revenue Beat and Narrowed Losses ↗
Via Chartmill
News headline image
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
From TriSalus Life Sciences
Via Business Wire
News headline image
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus (TLSI) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Proposes Public Offering
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
From TriSalus Life Sciences
Via Business Wire
News headline image
TriSalus Life Sciences Inc (NASDAQ:TLSI) Reports Q3 2025 Results with Strong Revenue Growth but Significant EPS Miss ↗
Via Chartmill
News headline image
TriSalus (TLSI) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
From TriSalus Life Sciences
Via Business Wire

Frequently Asked Questions

Is TriSalus Life Sciences, Inc. - Common Stock publicly traded?
Yes, TriSalus Life Sciences, Inc. - Common Stock is publicly traded.
What exchange does TriSalus Life Sciences, Inc. - Common Stock trade on?
TriSalus Life Sciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TriSalus Life Sciences, Inc. - Common Stock?
The ticker symbol for TriSalus Life Sciences, Inc. - Common Stock is TLSI on the Nasdaq Stock Market
What is the current price of TriSalus Life Sciences, Inc. - Common Stock?
The current price of TriSalus Life Sciences, Inc. - Common Stock is 2.810
When was TriSalus Life Sciences, Inc. - Common Stock last traded?
The last trade of TriSalus Life Sciences, Inc. - Common Stock was at 05/13/26 02:36 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.